NIRFLI with ICG
PreclinicalSmall molecule
NIRFLI with ICG is one of 24 small molecule programs targeting Tic Disorder. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
23 competitors in Tic Disorder
#DrugCompanyPhaseTrials
1Cymbalta
Jazz PharmaceuticalsApproved
Zofran
NovartisApproved
Zyprexa
MMODAG GmbH
Approved
Clozaril
LLife Extension Foundation Inc.
Approved
Lithobid
SSolvay Pharmaceuticals
Approved
Intuniv
PPromius Pharma, LLC
Approved
Reminyl
WWim Janssens
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Rituxan
RochePhase 2
Vitrakvi
BayerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Tic Disorder1 trial
Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders
Enrolling by invitation·TThe University of Texas Health Science Center, Houston··NCT00833599·283 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NIRFLI with ICG. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details